Results 131 to 140 of about 10,170,244 (414)

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

Molecular Oncology, EarlyView.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano   +17 more
wiley   +1 more source

Identification of mimicking anti-Ec with literature review: a case report

Zhongguo shuxue zazhi
[Objective] To identify a mimicking alloantibody, analyze its serological characteristics and antibody specificity, and explore transfusion strategies for mimicking alloantibody.
YU Zhanjuan, FAN Liangfeng, LI Jingwei, XIANG Dong   +3 more
doaj   +1 more source

Generation and characterization of D-dimer specific monoclonal antibodies for use in latex agglutination test.

PLoS ONE, 2019
The commercially available D-dimer assays used in the clinical practice often show differences in the results, and their specificity and sensitivity are rather unsatisfactory. Our aim was to develop a new monoclonal antibody against D-dimer with a proper
Beáta Török-Nagy, József Antal, Béla Dénes   +2 more
doaj   +1 more source

Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.

PLoS ONE, 2010
There is increasing interest in multi-allele vaccines to overcome strain-specificity against polymorphic vaccine targets such as Apical Membrane Antigen 1 (AMA1).
Kwadwo A Kusi, Bart W Faber, Vanessa Riasat, Alan W Thomas, Clemens H M Kocken, Edmond J Remarque   +5 more
doaj   +1 more source

INHERITANCE OF ANTIBODY SPECIFICITY

Journal of Experimental Medicine, 1974
Our data suggest that fine specificity of antihapten antibodies is a useful Mendelian marker of variable (V) genes. We found that some mouse strains (e.g., C57/BL6) consistently produced heteroclitic anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies ...
T. Imanishi, O. Mäkelä
semanticscholar   +1 more source

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

Molecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić, Florian Lüke, Steffi Treitschke, Andrea Coluccio, Martin Hoffmann, Giancarlo Feliciello, Adithi Ravikumar Varadarajan, Xin Lu, Kathrin Weidele, Catherine Botteron, Silvia Materna–Reichelt, Felix Keil, Katja Evert, Florian Weber, Thomas Schamberger, Michael Althammer, Jirka Grosse, Dirk Hellwig, Christian Schulz, Stephan Seitz, Peter Ugocsai, Anke Schlenska‐Lange, Roman Mayr, Ulrich Kaiser, Wolfgang Dietmaier, Bernhard Polzer, Jens Warfsmann, Kamran Honarnejad, Tobias Pukrop, Daniel Heudobler, Christoph A. Klein, Christian Werno   +31 more
wiley   +1 more source

Novel humanized monoclonal antibodies against ROR1 for cancer therapy

Molecular Cancer
Background Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for
Rong Wei, Xun Liao, Jiao Li, Xiaoyu Mu, Yue Ming, Yong Peng   +5 more
doaj   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

Molecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale, Li Li, J. Kyle Bruner, Melody Chou, Bao Nguyen, Jaesung Seo, Ruiqi Zhu, Mark J. Levis, Christine A. Pratilas, Donald Small   +9 more
wiley   +1 more source

Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis

Frontiers in Immunology, 2017
The identification of mutations that enhance antibody affinity while maintaining high antibody specificity and stability is a time-consuming and laborious process.
Kathryn E. Tiller, Ratul Chowdhury, Tong Li, Seth D. Ludwig, Sabyasachi Sen, Costas D. Maranas, Peter M. Tessier   +6 more
doaj   +1 more source

Structural Basis for Rabbit Hemorrhagic Disease Virus Antibody Specificity. [PDF]

J Virol, 2022
Leuthold MM, Kilic T, Devant JM, Landeta O, Parra F, Dalton KP, Hansman GS.   +6 more
europepmc   +1 more source